<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332006</url>
  </required_header>
  <id_info>
    <org_study_id>IBMCB - BS study</org_study_id>
    <nct_id>NCT01332006</nct_id>
  </id_info>
  <brief_title>Intra-bone Cord Blood Transplantation</brief_title>
  <official_title>Intra-bone Cord Blood Transplantation for Hematological Malignancies Lacking a HLA Suitable Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the great majority of hematological malignancies, hemopoietic stem cell (HSC) transplant&#xD;
      is the only possible cure. The source of HSC is usually bone marrow (BM) or peripheral blood&#xD;
      cell (PBSC) mobilized by granulocyte growth factor. Transplant needs a HLA compatible donor&#xD;
      weather related or unrelated. A suitable compatible donor can be found in at least 70% of the&#xD;
      patients. Thus, at least 30% of patients with indication for allogeneic HSC transplant are&#xD;
      not able to undergo the procedure because of the lack of a HLA compatible donor. Cord blood&#xD;
      (CB) cells represent another possible source, that needs a lower degree of HLA compatibility.&#xD;
      CB transplant, however, offers a lower number of HSC. Thus, adult patient rarely may benefit&#xD;
      from this source of stem cells, mainly beacuse thie body weight is too high to have ad&#xD;
      adequate number of cell per kg. Recently, experimental animal models confirmed that an&#xD;
      adequate recovery of allogeneic hemopoiesis can be achieved via intrabone injection, using a&#xD;
      1Log lower number of cells compared to the intravenous way (Yahata 2003, Castello 2004).&#xD;
      Safety and feasibility of intrabone infusion was verified by two clinical studies on humans:&#xD;
      the first was conducted by Ringden O. et al. in 18 patients using BM as a source of SC. No&#xD;
      side effects and complete engraftment of donor hemopoiesis was observed; the second one was&#xD;
      conducted by Frassoni et al. (Frassoni 2008) with CB as the source of HSC.&#xD;
&#xD;
      The aim of this study is to evaluate the intrabone infusion of compatible CB in patients with&#xD;
      haematological malignancies lacking a HLA matched donor.&#xD;
&#xD;
      We will perform:&#xD;
&#xD;
      evaluation of the engraftment kinetics; evaluation of the chimerism degree at 30, 60, 100&#xD;
      days, 6 months and 1 year after transplant; studies on immunological reconstitution and the&#xD;
      role of the NK compartment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of transplanted patients with successful engraftment at day +30</measure>
    <time_frame>30 days post transplantation</time_frame>
    <description>Engraftment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response with the analysis of global survival, survival without relapse, relapse incidence</measure>
    <time_frame>3 years from transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections' Incidence</measure>
    <time_frame>One year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism monitoring on selected cell populations</measure>
    <time_frame>Every three months and until one year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological reconstitution</measure>
    <time_frame>One year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute an Chronic GVHD</measure>
    <time_frame>One year after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Intra-bone injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-bone transplantation of hematopoietic stem cells from cord blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrabone injection</intervention_name>
    <description>All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.</description>
    <arm_group_label>Intra-bone injection</arm_group_label>
    <other_name>Intrabone Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intra-bone cord blood hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Intra-bone injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intra-bone cord blood hematopoietic stem cell transplantation</intervention_name>
    <description>Intra-bone injection of CB hematopoietic SCs after conditioning regimen</description>
    <arm_group_label>Intra-bone injection</arm_group_label>
    <other_name>No other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 65 years.&#xD;
&#xD;
          -  Patients affected by hematological malignancies without a HLA identical sibling donor&#xD;
             or unrelated donor.&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with ECOG &lt; 2.&#xD;
&#xD;
          -  Patients with blood creatine &gt; 2 mg/dl or with transaminase or cholestase index &gt; 5&#xD;
             times compared to normality upper limits.&#xD;
&#xD;
          -  Patients with Cardiac Fraction Ejection &lt; 40%.&#xD;
&#xD;
          -  Patients with DLCO &lt; 60% or Diffusing Lung Capacity of carbon monoxide attesting a&#xD;
             severe pulmonary insufficiency.&#xD;
&#xD;
          -  Patients with peripheral blast cell count over 10%.&#xD;
&#xD;
          -  Second neoplasia diagnosed no more than 2 years before.&#xD;
&#xD;
          -  Patients with active or suspected infection by fungi for which a therapeutic treatment&#xD;
             is ongoing.&#xD;
&#xD;
          -  HIV positive patients.&#xD;
&#xD;
          -  HCV-RNA and HBV-DNA positive patients&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Severe mental diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenico Russo, Full Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>USD TMO Adulti</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof Domenico Russo, Full Professor</last_name>
    <phone>+39/030/3996812</phone>
    <email>russo@med.unibs.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>USD TMO Adulti, Piazzale Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Malagola, Medical Doctor</last_name>
      <phone>+39/030/3996811</phone>
      <email>malagola@med.unibs.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Domenico Russo</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

